Table 3.

Summarized data from all studies listed in Table 1, by average duration of time since last anti-CD20 therapy

Duration of time since anti-CD20 therapy	Summarized SP rate, %	Summarized SC rate, %	Summarized SR rate, %
Pandemic influenza (N = 13 studies, 222 patients treated with anti-CD20 therapy)*
Active treatment, <3 mo	0-3330-34,40,61	0-2530-34,40
3-6 mo	1960	3860	38-4443
6-12 mo	5040	5040
>12 mo	66-10040,44	66-10040,44
Seasonal influenza (N = 12 studies, 252 patients treated with anti-CD20 therapy) †
Active treatment, <3 mo	8-2530,64	030,35
3-6 mo	56-8062	10-6062
6-12 mo	69-7763	2535	1742
>12 mo	23-7944,52	3-4344,52
Tetanus, diphtheria, and pertussis (12 studies, 309 patients treated with anti-CD20 therapy) ‡
Active treatment, <3 mo	10062	24-2536,62
3-6 mo	64-7367	9-3966,67
6-12 mo	66-9350,69	7-2069	31-6950,65,68,70
>12 mo	0-947,53	9-7546,53	047
Haemophilus influenzae B (3 studies, 52 patients treated with anti-CD20 therapy)
Active treatment, <3 mo
3-6 mo
6-12 mo		2938	73-77 after 1-2 doses68
>12 mo		8546
Hepatitis B (3 studies, 61 patients treated with anti-CD20 therapy) §
Active treatment, <3 mo
3-6 mo
6-12 mo
>12 mo	56-6454,71	5654
Hepatitis A (2 studies, 57 patients treated with anti-CD20 therapy)
Active therapy, <3 mo	047
3-6 mo
6-12 mo	47 (slightly lower than disease controls of 67)70
>12 mo
Polio virus (3 studies, 49 patients treated with anti-CD20 therapy) ǁ
Active treatment, <3 mo			2036
3-6 mo
6-12 mo
>12 mo			62, slightly lower than in disease controls (80)46
Pneumococcal conjugate (PCV-7) (1 study, 55 patients treated with anti-CD20 therapy)
Active treatment, <3 mo			5, compared with 21-50 in disease controls73
3-6 mo
6-12 mo
>12 mo
Pneumococcal polysaccharide (PCV-23) (7 studies, 217 patients treated with anti-CD20 therapy) ¶
Active treatment, <3 mo	2530	030
3-6 mo			19 to ≥6 serotypes66
6-12 mo	33 (to ≥7 serotypes) to 4168	20-2138,69	2965
>12 mo

^* See Tables 4 and 5 for meta-analyzed data. In all studies, SP, SC, and/or SR rates were similar or lower in anti-CD20–treated patients than healthy controls or disease controls. One study did not report the average duration since last dose of anti-CD20 therapy but had SP and SR rates of 0% and 0% to 9%, respectively.⁴⁵ One study indicated that patients had received anti-CD20 therapy <12 months ago but did not specify the average time interval, and reported a SP rate of 9%.⁵⁹

^†In all studies, SP, SC, and/or SR rates were lower in anti-CD20–treated patients than in healthy controls or disease controls.

^‡In all studies, SP, SC, and/or SR rates were similar or lower in anti-CD20–treated patients than healthy controls or disease controls. Other than in 2 studies^47,53 (a study of patients post–autologous stem cell transplant plus rituximab for non-Hodgkin lymphoma, and a study of pediatric patients treated with rituximab for relapsing/steroid-dependent idiopathic nephrotic syndrome) where the SP rates were only 0% to 9%, SP rates were moderate to high regardless of the duration that had elapsed from anti-CD20 therapy.

^§One study did not report the interval after anti-CD20 therapy during which patients were vaccinated.⁷² Overall values for anti-CD20–treated patients were similar to healthy controls ≥55 years and disease controls, but worse than healthy controls ≤35 years.

^ǁOne study did not report the interval after anti-CD20 therapy during which patients received vaccination but had a SR rate of 91%.⁵⁴

^¶All studies showed that SP, SC, and/or SR rates were lower in anti-CD20–treated patients compared with disease controls.